Background Older patients can be especially susceptible to antipsychotic-induced side effects, and the pharmacodynamic mechanism underlying this phenomenon remains unclear. We hypothesized that age-related epigenetic alterations lead to decreased expression and functionality of the dopamine D2 receptor (D2R), contributing to this susceptibility. Methods In this study, we treated young (2-3 months old) and aged (22-24 months old) C57BL/6 mice with the D2R antagonist haloperidol (HAL) once a day for 14 days to evaluate HAL-induced motor side effects. In addition, we pretreated separate groups of young and aged mice with histone deacetylase (HDAC) inhibitors valproic acid (VPA) or entinostat (MS-275) and then administered HAL. Results Our results show that the motor side effects of HAL are exaggerated in aged mice as compared to young mice and that HDAC inhibitors are able to reverse the severity of these deficits. HAL-induced motor deficits in aged mice are associated with an age-and drug-dependent decrease in striatal D2R protein levels and functionality. Further, histone acetylation was reduced while histone tri-methylation was increased at specific lysine residues of H3 and H4 within the Drd2 promoter in the striatum of aged mice. HDAC inhibitors, particularly VPA, restored striatal D2R protein levels and functionality and reversed age-and drug-related histone modifications at the Drd2 promoter. Conclusions These results suggest that epigenetic changes at the striatal Drd2 promoter drive age-related increases in antipsychotic side effect susceptibility, and HDAC inhibitors may be an effective adjunct treatment strategy to reduce side effects in aged populations.
Introduction
Antipsychotic drugs (APDs) are commonly prescribed to the elderly for the treatment of psychosis and for the behavioral and psychological symptoms of dementia (BPSD) (Agid et al. 2007; Aupperle 2006; Gareri et al. 2014a, b; Etchepare et al. 2016) . However, the use of such drugs is problematic because of the increased severity and frequency of side effects in aged populations (Gareri et al. 2006; Singh and Hodgson 2010) . The most common side effects induced by APDs in general are extrapyramidal side effects (EPS), including parkinsonism, bradykinesia, muscle rigidity, and tremor, which have a higher occurrence and severity in elderly patients. Though pharmacokinetic changes could be partially responsible for this increase in side effect occurrence and severity (Sweet and Pollock 1998) , pharmacodynamic alterations during aging are likely a key factor (Graff-Guerrero et al. 2015; ).
Almost all APDs have some degree of affinity for antagonizing the dopamine D2 receptor (D2R), as decreased activity Electronic supplementary material The online version of this article (doi:10.1007/s00213-017-4629-2) contains supplementary material, which is available to authorized users. of mesolimbic D2R is partially responsible for the therapeutic efficacy of these drugs (Miyamoto et al. 2004 ). However, off-target blockade of D2R in the nigrostriatal and striatopallidal pathways is thought to play a significant role in the manifestation of EPS (Greenbaum and Lerer 2015) Unsurprisingly then, nigrostriatal and striatopallidal D2Rs are known to be altered during aging (Kaasinen et al. 2000; Volkow et al. 1998; Wong et al. 1997) , with decreases in D2R expression (Ishibashi et al. 2009 ) and ligand binding (Antonini et al. 1993; Rinne et al. 1993; Volkow et al. 1996) in older age. For example, in humans, age-related decreases in extrastriatal D2R have been reported in the frontal cortex (Kaasinen et al. 2002; Greenbaum and Lerer 2015) . In rodents, striatal D2R ligand binding is reduced to 41% in aged compared to younger rats (Hoekzema et al. 2010; Suzuki et al. 2001) . Recently, it was shown that the therapeutic dosing threshold predicted by D2R/3R occupancy was reduced from ∼65 to 50% binding affinity in young versus aged patients (Graff-Guerrero et al. 2015) , suggesting a potentially narrower therapeutic window in elderly patients. These age-related alterations in the expression and functionality of D2R underlie the increased sensitivity of older patients to these adverse effects (Shiroma et al. 2010) .
Histone modifications have consistently been shown to regulate neural gene expression during development and in response to environmental stimuli (Graff and Tsai 2013) , and unsurprisingly epigenetic alterations, specifically histone modifications, have been associated with aging (Maleszewska et al. 2016) . In concert, epigenetic changes accumulate during aging and can affect brain function at the cellular and molecular levels (Graff and Tsai 2013; Peleg et al. 2010; Tang et al. 2011) . Acetylation of histones at specific lysine residues is decreased in aged rats (Kozurkova et al. 1995) , and increased histone deacetylase (HDAC) and decreased histone acetyltransferases (HAT) are evident in aged cells (Dagnas and Mons 2013; Graff and Tsai 2013; Willis-Martinez et al. 2010) . HDAC inhibitors can restore memory function in aged mice through enhancement of LTP at hippocampal synapses (Castellano et al. 2012; Zeng et al. 2011) . Importantly, our recent study showed that the HDAC inhibitors valproic acid (VPA) and MS-275 can increase the therapeutic effects of haloperidol (HAL) in aged mice, partially by modulation of histone acetylation at the c-fos promoter in the shell of the nucleus accumbens and prefrontal cortex (Montalvo-Ortiz et al. 2014) . Taken together, the changing epigenetic landscape in the aged brain may provide a mechanistic explanation for the profound deficits in pharmacotherapeutic success in older patients.
Though D2R expression and function are likely to affect a patient's susceptibility to motor deficits, it is unclear if aged patients suffer greater side effects due to this mechanism. In particular, it is unknown if the changing epigenetic landscape that is associated with aging may ultimately explain the increased side effect occurrence in aged populations. It has been reported that epigenetic alterations in dopaminergic receptors accrue during chronic stress and drug administration (Aoyama et al. 2014; Moriam and Sobhani 2013; Nieratschker et al. 2014) , and similar epigenetic changes are associated with certain psychiatric disorders, including eating disorders (Abdolmaleky et al. 2008; Frieling et al. 2010; Vucetic et al. 2012) . In this study, we hypothesized that one of the central mechanisms underlying increased APDinduced side effects in aged patients is driven by epigenetic changes accumulated during aging. To test our hypothesis, we demonstrate age-dependent differences in motor deficit severity with HAL administration between young and old mice and uncover an epigenetic mechanism for this difference. In particular, we show that age-related increases in motor side effects with HAL are associated with histone modifications at the Drd2 promoter leading to decreased D2R expression and functionality in the striatum. Further, we demonstrate that co-treatment with HDAC inhibitors reverses these age-related histone modifications and restores D2R expression and functionality in the striatum. Taken together, our results suggest an important mechanism driving age-related changes in APD-induced side effects and a possible translational approach to ameliorating these symptoms in the clinic.
Methods and materials Animals
Young (2-3 months old) and aged (20-24 months old) C57BL/6 male mice (n = 6-8/group for behavioral tests, n = 4-5/group for biochemical analysis) from the Charles River Laboratories (Bar Harbor, Maine) were used for this study. We chose this strain because it is the most common mouse strain used for preclicinal studies. Animals were group housed on a 12-h light/dark cycle and given food and water ad libitum. All procedures were performed according to NIH guidelines for the treatment of animal subjects and the Current Guide for the Care and Use of Laboratory Animals (2011, eighth edition) under a protocol approved by the Northwestern University Animal Care and Use Committee.
Drugs
All drugs used were purchased from Sigma (St. Louis, MO), and every dose was prepared on the day of administration. HAL (0.01, 0.1, 0.5 mg/kg) and MS-275 (10 mg/kg) were first dissolved in 50 μL of glacial acetic acid and brought up to the final dose volume in 0.9% saline with pH adjusted to 5-6 and titrated with 0.1 M NaOH. VPA (400 mg/kg) was dissolved in 0.9% saline with pH 7.3. All compounds and vehicles were administered intraperitoneally (i.p.) at a constant volume of 10 mL/kg of body weight once a day for 14 consecutive days. VPA (400 mg/kg) or MS-275 (10 mg/kg) was injected 30 min before HAL (0.01 mg/kg) administration.
Behavioral tests
For all behavioral experiments, mice were acclimated to a soundproof behavioral testing room for at least 30 min prior to testing, and assays were performed during the light part of the 12-h light/dark cycle (for a detailed description of the experimental design (drug paradigm, behavioral tests performed, and tissue collection), refer to Supplemental Fig. 1 ).
Catalepsy
To assess catalepsy, the Step Down assay was used. A plastic rod (1-cm diameter) was suspended 3.5 cm above a laboratory bench in a soundproof behavioral room. Thirty minutes after drug injection, the front paws of the animal were placed on the rod while the hind paws rested on the bench. The duration of a cataleptic episode was defined as the time to step off from the rod during a 300-s trial (Fink-Jensen et al. 2011 ).
Motor coordination
The TSE RotaRod System (Bad Homburg, Germany) was used to assess motor coordination after drug treatment. Mice were placed on an accelerating rod (4-40 rpm during the first 5 min) for 10 min, and the latency to fall from the rod was recorded. A total of four trials were conducted with a 10-min inter-trial interval. The average latency to fall from the rod across the four trials was calculated (Kirschbaum et al. 2009 ) and used as the endpoint for this study.
Spontaneous locomotor activity
Locomotor activity was measured using the open field test. An automated tracking system (Any-Maze) was used to track the locomotion of each subject in an open, Plexiglass box (25 cm × 25 cm × 25 cm) that was evenly illuminated. Locomotion was defined as the distance traveled (cm) during the 10-min trial (Viana et al. 2013) .
Western blot
Tissue samples were collected using 300-μm-thick coronal cryosections of the striatum using a 1-mm microdissection punch and homogenized in 3% (w/v) ice-cold Tissue Protein Extraction Reagent (T-PER; Thermo Scientific) and then centrifuged at 20,000×g for 10 min at 4°C. Protein content was measured using the BCA protein assay kit (Thermo Scientific) according to the manufacturer's instructions. Samples were transferred onto a nitrocellulose membrane (Invitrogen). Blots were immunostained overnight at 4°C with primary antibodies against D2R, H3ac, H4ac, and H4K12ac (Millipore); H3K9ac (Abcam); and H3K27ac (Active Motif). The membrane was then incubated with HRP-conjugated goat antimouse or goat antirabbit secondary antibodies for 2 h at room temperature. Blotted protein was detected and quantified using the ChemiDoc™ MP Imaging System (Bio-Rad), and levels of target protein expression were normalized to β-actin, as described previously (Montalvo-Ortiz et al. 2014) .
cAMP assay
The cAMP-Glo Assay kit (Promega, WI) was used following the manufacturer's instructions with slight modifications. Brain tissue was diluted in induction buffer and heated at 70°C for 5 min. Samples were then incubated with DA (10 μM) or forskolin (10 μM) followed by quinpirole (starting dose of 250 μM) for 30 min. cAMP-Glo Lysis Buffer was then added to the samples, and the plate was incubated for 15 min. Samples were then incubated with cAMP-Glo detection solution containing cAMP-Glo reaction buffer for 20 min and incubated with Kinase-Glo reagent for 10 min. Luminescence (in RLU), which is inversely proportional to the intracellular cAMP concentrations, was measured by using a plate-reading luminometer. Responses by percent were then fitted by non-linear regression analysis using GraphPad Prism software (San Diego, CA). To quantify agonist potency, EC50 values (the concentration of agonists required to produce 50% of the maximum effect) were also calculated. Each concentration of quinpirole was tested five times in triplicate.
Histone acetyltransferases and histone deacetylase activity assay
Nuclear extracts from the striatum were prepared as previously described (Montalvo-Ortiz et al. 2014) . HAT and HDAC activities were measured by using a colorimetric assay kit (Epigentek, NY) according to the manufacturer's instructions and previously published protocols (Siuda et al. 2014; Toussirot et al. 2013) . Briefly, this ELISA-based assay directly detects HAT/HDACconverted deacetylated products, which is proportional to enzyme activity. The ratio of deacetylated products was m e a s u r e d b y r e a d i n g a b s o r b a n c e u s i n g a spectrophotometer at 450 nm. HAT or HDAC activities were expressed as OD/milligram.
Chromatin immunoprecipitation assay
The commercially available Magna ChIP™ G Tissue Kit (17-20,000, Millipore) was used, and the published protocol was followed (Montalvo-Ortiz et al. 2014) . Fragmented chromatin lysate (400-600 bp size determined by agarose gel electrophoresis) was immunoprecipitated with 5 μg of antibody directed against H3K27ac, H3K9ac, H4K12ac, or H3K27me3. The DNA-histone complex was incubated with salmon sperm DNA/protein A-agarose beads for 1 h to estimate non-specific binding. The DNA-histone complex was eluted from the beads and dissociated at 65°C for 4 h under high-salt conditions. Proteins were digested using proteinase K treatment, and the associated DNA was precipitated with 100% ethanol and resuspended in 80 μl of PCR-grade water.
Quantitative real-time PCR
The levels of interaction between modified histones and the Drd2 gene promoter were determined by measuring the amount of histone-associated DNA, isolated via chromatin immunoprecipitation (ChIP), using quantitative real-time PCR (qRT-PCR). We used custom primers for the Drd2 promoter (forward: 5′-CTGGAGCCAAAAGCAGTCTG-3′, reverse: 5′-TCCTTCAGGTTTCCGACGCC-3′) and the β-actin promoter (forward: 5′-GCGTCCACCCGCGAGTACAA-3′, reverse: 5′-TCCATGGCGAACTGGTGGCG-3′) used as control. Input and immunoprecipitated DNA amplification reactions were run in triplicate in the presence of SYBR Green (Applied Biosystems) using an ABI Prism 7700 thermocycler (Applied Biosystems, Foster City, CA). Ct values from each sample were obtained using the Sequence Detector 1.1 software. Ct values were normalized to the endogenous gene, beta actin, to obtain a percent input. Fold differences (drug-treated versus control) were then determined using the ΔΔC t method.
Statistical analysis
All statistical analyses were conducted using the GraphPad Prism software (San Diego, CA). Data are expressed as mean ± standard error of the mean (SEM). Two-way analysis of variance (ANOVA) was used to detect age and treatment effects followed by a multiple comparisons analysis using Bonferroni's post hoc method. For the cAMP accumulation analysis, results are presented as percentage of the maximal relative luminescence units (RLU), and the concentrationresponse curves were fitted by a non-linear regression analysis. Significant differences are reported as p < 0.05.
Results

Histone deacetylase inhibitors decrease haloperidol-induced extrapyramidal side effect-like behaviors in aged mice
To test whether epigenetic changes might underlie the increase in APD side effects in an aged population, we first assessed whether we could model this increase in side effects in mice. Because the classical antipsychotic HAL has been reliably shown to induce cataleptic behavior in mice (Campbell and Baldessarini 1981) , we first set out to establish the severity of HAL-induced catalepsy in young (2-3 months old) and aged (20-24 months old) cohorts. Using the Step Down assay, a well-validated assay of cataleptic behavior (Campbell and Baldessarini 1981) , we assessed both cohorts' motor function after daily administration of HAL i.p. for 14 days. Two-way A N O VA s h o w e d s i g n i f i c a n t e f f e c t s o f a g e (F 1,51 = 46.59, p < 0.0001), treatment (F 3,51 = 62.76, p < 0 . 0 0 0 1 ) , a n d a g e × t r e a t m e n t i n t e r a c t i o n (F 3,51 = 8.19, p < 0.001) on the duration of cataleptic episodes in a dose-dependent manner. In young mice, post hoc analysis revealed significant increases in the duration of cataleptic episodes in mice that received HAL at 0.1 (p < 0.05) and 0.5 mg/kg (p < 0.01) but not at 0.01 mg/kg, as compared to age-matched control mice (Fig. 1a) . By contrast, aged mice showed significant increases in the duration of cataleptic episodes at all doses of HAL (p < 0.01) compared to their age-matched controls. When comparing the young and aged mice, HAL administration increased the duration of cataleptic episodes in the aged mice at all three doses tested. This mouse model demonstrates that HAL-induced catalepsy increases with age and that this paradigm is useful to investigate the biochemical mechanisms underlying the increase in severity of APD-induced side effects associated with aging.
To test our hypothesis that epigenetic changes might mediate the differences in cataleptic behavior, we assayed multiple cohorts of young and aged mice after being administered vehicle or HDAC inhibitors (VPA or MS-257) and subsequent vehicle or HAL daily for 14 days. Interestingly, two-way ANOVA revealed significant effects of age (F 1,71 = 4.29, p < 0.05) and treatment (F 5,71 = 19.89, p < 0.0001) after daily pre-treatment with VPA (400 mg/kg) or MS-257 (10 mg/kg). VPA or MS-275 significantly diminished the duration of HAL-induced cataleptic episodes in both young and aged mice with a much larger difference observed in the aged cohort. Post hoc analysis revealed significant decreases in the duration of cataleptic episodes for aged mice given HAL + VPA (p < 0.05)-and HAL + MS-275 (p < 0.001)-treated groups as compared to HAL-treated age-matched mice (Fig. 1d ).
Because previous publication has shown that APDs disrupt coordi nation and m otor learning in an age-dependent manner (Kirschbaum et al. 2009 ), we assayed both young and aged mice on the accelerating rotarod. Significant effects of age (F 1,57 = 34.34, p < 0.0001) and treatment (F 3,57 = 30.24, p < 0.001) were found on the latency to fall from the rotarod. HAL significantly impaired motor function by decreasing the latency to fall off the rotarod in a dose-dependent manner in both aged and young mice, and again, aged mice had the largest decrease in latency (Fig. 1b) . Consistent with the catalepsy results, significant effects of age (F 1,71 = 26.27, p < 0.0001), treatment (F 5,71 = 9.720, p < 0.0001), and age x treatment interaction (F 5,71 = 2.849, p < 0.05) were observed when VPA or MS-275 pretreatment was combined with HAL administration on the latency to fall. Bonferroni's post hoc testing revealed a significant increase in the latency to fall in aged mice treated with HAL + VPA relative to aged mice treated with HAL alone (p < 0.05). This effect was also found in young mice treated with HAL + VPA as compared to HAL alone (p < 0.001) (Fig. 1e) . No significant differences were found between HAL and HAL + MS-275 in both young and aged groups.
Locomotor activity was also assessed in the open field test to evaluate whether HAL decreases locomotor activity differently in both young and aged mice. Two-way ANOVA showed significant effects of age (F 1,33 = 5.21, p < 0.05) and treatment (F 3,33 = 11.49, p < 0.0001) on the distance traveled in the open field. Significant decreases were found on the distance traveled of aged mice treated with 0.1 (p < 0.001) and 0.5 mg/kg (p < 0.001) but not 0.01 mg/kg of HAL as compared to age-matched controls. Additionally, no statistically significant differences in the young cohort were observed (Fig. 1c) . Again, when VPA or MS-275 pretreatment was combined with HAL administration, we observed significant effects of age (F 1,54 = 14.17, p < 0.001) and treatment (F 5,54 = 3.931, p < 0.01) in the distance traveled. In aged mice, VPA and MS-275 alone or combined with HAL demonstrated a trend towards increased locomotor activity as compared to HAL-only-treated mice, but this comparison did not reach statistical significance (Fig. 1f) . Taken together, our results suggest that HAL induces increasingly severe motor side effects in older versus younger mice and that pretreatment with HDAC inhibitors is sufficient to reverse the severity of these side effects. Histone deacetylase inhibitors restore dopamine D2 receptor protein levels and functionality in the striatum of aged mice Age-related alterations in the homeostasis of the dopaminergic system influence the action of APDs targeting dopamine receptors (Hoskins et al. 1991; Leon et al. 2010) . One of the most important alterations is found in the activity of the striatal D2R, which mediates the severity of motor side effects induced by APDs. Because aged mice have an increase in the severity of APD-induced motor deficits, we examined whether D2R changes in the striatum of these mice. In addition, we examined whether daily treatment with HAL with or without HDAC inhibitors might change the levels of the D2R protein via Western blot. Two-way ANOVA revealed significant effects of age (F 1,22 = 25.57, p < 0.0001) and treatment (F 3,22 = 5.24, p < 0.01) on the D2R protein levels. Bonferroni's post hoc analysis showed a significant age-related decrease in the striatal D2R protein of HAL-treated mice (0.01 mg/kg, p < 0.05) compared to age-matched controls (Fig. 2a, b) . In addition, striatal D2R protein levels increase in both cohorts but were more apparent in the young mice. When comparing young and aged mice after pretreatment with HDAC inhibitors and HAL, significant effects of treatment (F 5,36 = 8.55, p < 0.001) on the D2R protein levels in the striatum were observed (Fig. 2c) . In aged mice, significant increases in D2R protein levels were found in HAL + VPA-treated mice (p < 0.01) and a trend of increased D2R protein levels is observed in the HAL + MS-275-treated aged mice as compared to vehicle-or HAL-treated aged mice. These results indicate that the impairment of aged mice to appropriately increase D2R protein levels upon HAL administration is consistent with the increased severity of motor side effects in the behavioral assay. Furthermore, the decrease in D2R protein levels in aged mice at baseline and after HAL administration may be reversed by treatment with HDAC inhibitors, particularly with VPA, which implies the possibility that age-related differences in the severity of side effects observed upon HAL administration may be mediated by histone modifications.
Though HDAC inhibition can reverse the decrease in D2R expression in aged mice, it is still unclear if D2R function is similarly affected, evident through D2R's inhibition of adenylyl cyclase and cAMP production (Neve et al. 2004 ).
To investigate D2R functionality, we measured the effects of dopamine (DA) (10 μM) and quinpirole (D2R agonist) on intracellular cAMP concentrations of striatal tissue extracts from young and aged mice. Two-way ANOVA revealed significant effects of age (F 1,12 = 505.42, p < 0.0001), treatment (F 1,12 = 288.87, p < 0.0001), and age × treatment interaction (F 1,12 = 124.28, p < 0.0001) in striatal D2R function. Significant increases in D2R function were found in young mice after DA (10 μM) incubation (p < 0.0001) but not in aged mice (Fig. 3a) . We found that cAMP accumulation was significantly higher in the striatal tissues of aged mice (EC50: young = 6.35 × 10 −9 , aged = 1.41 × 10 −6 ; F 1,62 = 154.8, p < 0.0001) (Fig. 3b, d , f). VPA and MS-275 combined with HAL treatment significantly decreased cAMP accumulation after incubation with escalating doses of quinpirole in the striatal tissues of aged mice (Fig. 3d, f) . No differences were observed among the different treatment groups of young mice (Fig. 3b, c, e) . These findings suggest that HDAC inhibitors combined with HAL treatment restore D2R functionality in the striatum of aged mice.
Histone deacetylase inhibitors increase acetylation and decrease tri-methylation at the Drd2 promoter in the striatum of aged mice
To directly assay the changes in histone modifications influencing D2R protein levels and function, we conducted a ChIP assay at the Drd2 promoter followed by qRT-PCR to investigate the modifications in acetylation and methylation at specific H3 and H4 lysine residues. Results of the specific histone modifications in striatal tissues are found in the following: H3K9 acetylation (H3K9ac): Two-way ANOVA showed significant effects of treatment (F 5,32 = 44.25, p < 0.0001) and age × treatment interaction (F 5,32 = 4.238, p < 0.01) in H3K9ac binding at the Drd2 promoter. An age-related decrease in H3K9ac binding was found, and HAL significantly increased H3K9ac binding in the striatum of young but not aged mice. However, significant increases in H3K9ac binding were found in both groups of mice treated with VPA (p < 0.01), HAL + VPA (p < 0.0001), and HAL + MS-275 groups (p < 0.05) relative to age-matched controls (Fig. 4a) .
H3K27 acetylation (H3K27ac): Two-way ANOVA showed significant effects of age (F 1 , 3 5 = 20.32, p < 0.0001), treatment (F 5,35 = 11.46, p < 0.0001), and age × treatment interaction (F 5,35 = 6.097, p < 0.001) in H3K27ac binding at the Drd2 promoter of the striatum. H3K27ac binding was significantly decreased in aged mice treated with HAL relative to treatment-matched young mice (p < 0.0001). However, a significant increase in H3K27ac binding was found in aged mice treated with HAL + VPA (p < 0.001) and HAL + MS-275 (p < 0.05) as compared to aged mice treated with vehicle. No significant changes in H3K27ac binding were observed in young mice treated with any of the HDAC inhibitors (Fig. 4b) .
H4K12 acetylation (H4K12ac): Two-way ANOVA showed significant effects of age (F 1,24 = 12.35, p = 0.01), treatment (F 5,24 = 40.06, p < 0.0001), and an age × treatment interaction (F 5,24 = 18.59, p < 0.0001) in H4K12ac binding at the Drd2 promoter. We found significant decreases of H4K12ac binding in aged mice treated with vehicle (p < 0.01) or HAL (p < 0.05) as compared to their treatment-matched young mice. However, significant increases in H4K12ac binding were found in aged mice treated with VPA (p < 0.001), HAL + VPA (p < 0.001), MS-275 (p < 0.05), and HAL + MS-275 (p < 0.05) relative to age-matched control. Again, young mice did not show significantly different changes between any of the treatment groups (Fig. 4c) .
H3K27 tri-methylation (H3H27me3): Two-way ANOVA showed significant effects of age (F 1 , 3 5 = 73.66, p < 0.0001), treatment (F 5,35 = 52.01, p < 0.0001), and age × treatment interaction (F 5,35 = 57.08, p < 0.0001) in H3K27me3 at the Drd2 promoter of the striatum. H3K27me3 binding was significantly increased in aged mice treated with vehicle or HAL (p < 0.0001) as compared to treatment-matched young mice. However, significant decreases of H3K27me3 binding were found in aged mice treated with HAL + VPA (p < 0.0001) or HAL + MS-275 (p < 0.01) as compared to aged mice treated with vehicle or HAL. No significant changes were detected in the young mice at any treatment group (Fig. 4d) .
The protein levels of the H3 and H4 total and residual markers: Protein levels of these histone acetylation and Supplementary Figs. 2 and 3) . Our results indicate that there was no significant difference in the bulk acetylated H3ac and H4ac between young and aged mice with or without HAL or HDACi treatment (Fig. S2) . However, the protein levels of the individual histone acetylation (H3K27ac, H4K12ac, and H3K9ac) and methylation (H3K27me3) markers were increased or decreased (Fig. S3) in parallel with the acetylation and methylation level measured by the ChIP assay at the Drd2 promoter (Fig. 4) . In summary, these results suggest that there is a substantial increase in repressive histone marks and a decrease in permissive histone marks at the Drd2 locus in aged versus young mice. Further, these results show that while the epigenetic landscape of young mice at this promoter is relatively insensitive to HDAC inhibition, aged mice have a substantially altered epigenetic landscape at the Drd2 promoter with HDAC inhibitor treatment.
Histone deacetylase inhibitors decrease histone deacetylase and increase histone acetyltransferase activities in the striatum of aged mice
Because our behavioral and biochemical data demonstrate that aged mice respond particularly strongly to HDAC inhibitors, we hypothesized that HDAC activity may be a driver of these age-related effects. To measure HDAC activity at baseline and after HAL administration, we used an enzyme-based colorimetric assay with striatal tissue extracts. Two-way ANOVA revealed significant effects o f a g e ( F 1 , 3 6 = 1 3 0 4 , p < 0 . 0 0 0 1 ) , t r e a t m e n t (F 5,36 = 92.88, p < 0.0001), and age × treatment interaction (F 5,36 = 69.66, p < 0.0001) on total HDAC activity. Significant increases in HDAC activity were found in Fig. 3 aged mice treated with vehicle and HAL as compared to either vehicle-or HAL-treated young mice (p < 0.0001). However, the decrease in HDAC activity was significantly greater in aged mice treated with VPA (p < 0.05), HAL + VPA (p < 0.05), MS-275 (p < 0.0001), or HAL + MS-275 (p < 0.0001) as compared to their age-matched control or HAL-treated mice. Interestingly, there were no significant differences between treatment groups in the young mice nor any changes in either group with HAL administrated alone (Fig. 5a ).
As balances in gene expression are also controlled by active histone acetylation, we evaluated histone acetyl transferase (HAT) activity in both aged and young mice treated with vehicle or HAL and mice pretreated with HDAC inhibitors. Two-way ANOVA revealed significant effects of treatment (F 5,36 = 15.96, p < 0.0001) and age × treatment interaction (F 5,36 = 6.26, p < 0.001) on HAT activity in the striatum. HAT activity was significantly decreased in aged mice when compared to young mice at baseline and under HAL conditions (p < 0.05). However, significantly greater increases in HAT activity were found in aged mice treated with VPA, HAL + VPA (p < 0.01), MS-275, and HAL + MS-275 (p < 0.05) as compared to age-matched controls or mice treated with HAL alone. Interestingly, HAL induced an increase in HAT activity in young mice but not in aged mice. However, similar to the activity of the HDAC inhibitors, there was no change in HAT activity under any treatment with VPA or MS-275 in the young mice (Fig. 5b) . This suggests that only aged mice show significant changes in HDAC or HAT activity upon HDAC inhibition. In addition, the increase in HAT activity after HAL in young but Fig. 4 Epigenetic alterations at the striatal DRD2 promoter after HAL and HDAC inhibitor administration in young and aged mice. Histone acetylation H3K9ac, H3K27ac, and H4K12ac markers (a-c) and histone methylation H3K27me3 marker (d) at the Drd2 promoter of the striatum in young (gray bars) and aged (black bars) mice were measured as the percentage of input with ChIP assay and RT-PCR. Results indicated a significant decrease in H3K9ac, H3K27ac, and H4K12ac, and significant increase in H3K27me3 in VEH groups in aged mice as compared to young mice. VPA and MS-275 significantly increased H3K9ac, H3K27ac, and H4K12ac at the Drd2 promoter of the striatum of aged mice. *p < 0.05, **p < 0.01, ***p < 0.001. n = 6-8/group not aged mice may suggest that the lack of compensatory increase in D2R with HAL may be due to blunted HAT activity in aged populations.
Discussion
We demonstrated that the severity of HAL-induced motor side effects differs between young and aged mice, and through detailed biochemical and pharmacological analyses, our data suggest that the epigenetic regulation of the Drd2 promoter is likely to underlie some of the observed behavioral differences. Our data provide strong evidence indicating that histone hypoacetylation and hypermethylation at certain histone residues associated with the Drd2 promoter in the striatum result in reduced D2R protein levels and subsequent dysfunction, thus contributing to the exacerbated motor side effects in aged mice. These histone modifications are likely caused by the increased HDAC activity and decreased HAT activity observed in the striatum of these aged mice. In addition, while young mice show a compensatory response in upregulating D2R after HAL administration, likely mediated through increased HAT activity, the aged mice lack this compensatory increase in both HAT activity and D2R expression. This blunted response is likely to be associated with the increased sensitivity of aged mice to the motor side effects induced by chronic HAL administration. Lastly, we show that pharmacological inhibition of HDACs, particularly VPA, diminished the severity of HAL-induced motor side effects in aged mice, most likely through the restoration of D2R function in the striatum. Overall, these data suggest that histone modification may be a novel adjuvant therapy to reduce APD-related side effects in elderly patients. To examine the phenomenon of age-dependent increases in APD-related side effects, we chose to examine the robust and reproducible deficits associated with a classical APD, HAL.
We found that HAL increased the duration of cataleptic episodes, an often used marker of APD side effects (Ionov and Pushinskaya 2013) , in a dose-dependent manner in both young and aged mice. However, the severity of cataleptic episodes is increased in aged mice, consistent with previous reports (Barnes et al. 1990; Campbell et al. 1988; Wiley and Evans 2008) . In addition, similar results were obtained using the rotarod, a test of motor dysfunction (Kirschbaum et al. 2009 ). Although age-related differences were not significant in locomotor activity in the open field, higher doses of HAL resulted in decreased locomotion in aged mice. These findings present strong evidence that our model of age-dependent increases in motor side effect severity is robust and helps to contextualize the subsequent pharmacological and biochemical analyses.
Multiple studies from the literature have suggested differences in APD pharmacokinetics and pharmacodynamics between younger and older patient populations ), though it is unclear what exact mechanisms underlie these changes and what contributions each makes to the resulting increase in side effect severity. Consistent with the clinical literature, our previous work (Montalvo-Ortiz et al. 2014 ) also observed changes in both these processes. Pharmacokinetically, we demonstrated increased accumulation of HAL in the plasma and brain of aged mice compared to controls in a dose-dependent manner. Importantly, however, the plasma and brain concentrations at the lowest dose of HAL assayed (0.01 mg/kg) were comparable in both groups. Because our behavioral and biochemical experiments used this dose of HAL, it is very likely that the changes in side effect severity measured by our assays are truly differences in the pharmacodynamic responses due to age (Montalvo-Ortiz et al. 2014) .
Age-related changes in dopaminergic signaling are thought to mediate the increased severity of APD-induced side effects found in elderly patients, and this change may underlie the pharmacodynamic response changes associated with age. In line with this, we assessed the functionality of the D2R in the striatum by measuring adenylyl cyclase activity following stimulation with DA and quinpirole (selective D2R agonist). We found that D2R function was impaired in the striatum of aged mice as shown by the reduced ability of DA and quinpirole to decrease cAMP levels. Along with these findings, we observed an age-related decrease in striatal D2R protein upon HAL administration. These results suggested that D2R was uniquely altered during aging and that the decrease in available D2R might explain both the decreased cAMP catabolism and more severe D2R-mediated motor deficits apparent in elderly patients treated with APDs, though a more complex mechanism cannot be ruled out. A recent study looking at dose reduction and D2/3R occupancy in elderly patients concluded that the percentage binding of DA to the receptor is likely correlated with the manifestation of EPS (Graff-Guerrero et al. 2015) . Though a specific therapeutic threshold was difficult to establish, the implication from this study and our own data is that the decreased D2R expression may make small changes in endogenous DA transmission more drastic in older patients, which may result in greater changes in the percentage of occupied D2R due to an age-related low baseline amount of the receptor. This narrowing therapeutic window with age may be explained by the decreased D2R and epigenetic modifications found in our study, though further investigation is necessary to confirm this in patients. Previous rodent studies examining D2R after chronic HAL administration have shown a compensatory increase in striatal D2R (Cazorla et al. 2014) , similar to the young cohort of mice in our study. Interestingly, the ability of the aged cohort of mice to upregulate D2R after HAL administration was absent or greatly reduced in a dose-dependent manner. These results suggest that not only is baseline D2R expression reduced in aged mice, but they lack the ability to sufficiently upregulate the receptor upon its antagonism. Consistent with this, young mice show an increase in HAT activity upon HAL administration while aged mice lack this increase. Taken together, this further supports that a more restrictive and less plastic epigenetic landscape exists in aged populations and that this epigenetic constraint may underlie the increase in side effect severity.
Precedence for epigenetic changes as a strong driver of behavior in aging has been previously demonstrated in the aging-dependent cognitive decline associated with changes in histone modifications in the hippocampus of mice. Specifically, age-related memory impairment has been linked with decreased hippocampal acetylation of H4K12 (Peleg et al. 2010 ). More generally, increased di-methyl and tri-methyl H3K9, both repressive epigenetic marks, have been implicated in the aging processes (Sen 2014) . In our study, we show changes in specific histone residues: decreased acetylation of H3K9, H3K27, and H4K12 (markers associated with transcriptional activation) and increased H3K27 tri-methylation, (a marker associated with transcriptional repression) at the striatal Drd2 promoter. Concordantly, we found that the enzymes that modulate these histone modifications by removing (HDACs) or adding (HATs) acetyl groups are altered in aged versus young mice during APD administration. Our results are consistent with previous reports where HDAC activity is increased (Singh and Thakur 2014) while HAT activity is decreased (Li et al. 2002) during aging and also consistent with previously shown increases in striatal HDAC1 and HDAC2 with age (Willis-Martinez et al. 2010 ). This suggests the possibility that specific changes in these histones may represent a more generalizable mechanism behind the increase in all APD-induced side effects found in the elderly population, though this would need to be validated through much more rigorous experimentation with different behaviors and biochemical analyses of the brain regions that facilitate those behaviors.
Aberrant patterns of histone modifications that occur with aging can be pharmacologically corrected with HDAC inhibitors. In our previous work, we demonstrated that pretreatment with the HDAC inhibitors VPA and MS-275 can restore the impaired ability of aged mice to respond to HAL by increasing acetylation at the c-fos promoter in the nucleus accumbens shell and prefrontal cortex (Montalvo-Ortiz et al. 2014) . Previous studies have indicated that VPA can have protective effects on dopaminergic neurons (Chen et al. 2006; Kidd and Schneider 2010) , and recent findings suggested that VPA may directly affect D2R signaling by modulating histone acetylation at the Drd2 promoter (Lee et al. 2012) . HDAC inhibition promotes dopaminergic neuron survival by enhancing H3 acetylation, decreasing inflammatory factors, and increasing apoptosis in microglia (van Heesbeen et al. 2013) . Further, blockade of D2R signaling by APDs can induce histone H3 m o d i f i c a t i o n s i n t h e s t r i a t u m , i n c l u d i n g H 3 phospho-acetylation, H3pS10-acK14, associated with transcriptional activation (Lee et al. 2004) . Our study adds to evidence that HDAC inhibition may be beneficial to restoring proper D2R signaling and subsequently affected behavior. However, HDAC inhibitors are relatively broad spectrum and will influence the expression of many other genes other than Drd2. Therefore, the observed effects on the Drd2 promoter are likely only a subset of the effects precipitated by these drugs. Our previous report that HDAC inhibitors influence the c-fos promoter supports this hypothesis. Additional studies to investigate HDAC inhibitors' effects on other genes influenced by APDs, such as Htr2a, will provide a more complete perspective underlying the behavior induced by HDAC inhibition and the biochemical sequelae in the brain.
It should be noted that differences were observed between VPA and MS-275. VPA is more effective in restoring D2R in the striatum of aged mice, most likely due to a stronger effect of VPA in increasing histone acetylation, as evidenced by higher acetylated H3K9, H3K27, and H4K12 at the Drd2 promoter and lower HAT activity when compared with MS-275 under HAL conditions. The differences observed between these two HDAC inhibitors may be due to (1) broader effect of VPA at histone acetylation markers, (2) de-methylating action of VPA (Dong et al. 2010) , or (3) VPA's direct potentiation of DR2 activity by enhancing prostate apoptosis response-4 (PAR-4), an intracellular binding partner of DR2 (Lee et al. 2012) . The doses of VPA and MS-275 used in our study were selected based on previous publications that have examined both behavioral effects and brain-specific histone acetylation (Ren et al. 2004; Simonini et al. 2006; Tremolizzo et al. 2002) . The dose of 0.01 mg/kg selected for HAL-induced motor side effect in aged mice in this study was equivalent to the recommended daily dosages of 2.5 mg (two thirds lower than regular dose) for clinical use in aged patients (Markianos et al. 1999 ) Future studies are needed to identify the dose-dependent effects of HDAC inhibitors and optimal dosing for translation of HDAC inhibitors to a clinical population.
Another limitation of our study is the sole investigation of HAL, a classical APD, since atypical APDs are now more commonly prescribed. Our rationale for investigating HAL instead of an atypical APD was to develop a clear preclinical model to associate the changes in side effect severity with epigenetic alterations. It will be of utmost importance to investigate the generalizability of our current epigenetic results to the effects of atypical APDs in aged populations, and ongoing studies in our lab are investigating the atypical APD risperidone in age-related side effect severity. Lastly, our tissue collection method for the biochemical analyses precluded evaluation of more specific subregions within the striatum, as the dorsal and ventral striatum have distinct functional roles in motor function and resultant EPS (Bressan et al. 2003) . Future studies are needed to further characterize the regional selectivity of APD action in the striatum. In addition, further investigations of other brain regions, including the prefrontal cortex, will be helpful in understanding the changes in the epigenetic landscape with advanced age.
In summary, the results of our study suggest that hypoacetylation and hypermethylation at certain histone residues associated with the Drd2 promoter may mediate the decrease in the expression and functionality of D2R in the striatum of aged mice at baseline. Further, it is likely that the adaptability of this epigenetic landscape is impaired in aged compared to young mice, as evidenced by diminished compensation of D2R with HAL administration in aged mice. These age-related epigenetic changes are likely one of the mechanisms that contributes to increases in the sensitivity of older individuals to the motor-related side effects induced by HAL and other APDs. Importantly, HDAC inhibitors, particularly VPA, mitigate such adverse effects by restoring histone modifications in the striatum of aged mice and easing the epigenetic constraints on the Drd2 promoter. This mechanism of epigenetic regulation underlying APDs' behavioral effects in aged mice together with the reversal of side effects with HDAC inhibitors has significant clinical implications for the development of novel, adjuvant treatment strategies that couple HDAC inhibitors and APDs for better treatment results in aged populations.
